
CME INFORMATION
The Annual Meeting will provide continuing medical credits based on attendees’ participation in the activity. Attendees can claim credit by completing the evaluations for the sessions attended via a survey sent following the event. Completion of session and global evaluations is required, and evaluations may be submitted only once. Therefore, attendees should not begin evaluations until they have completed participation in the certified content for which they wish to claim credit.
The deadline to claim CME and MOC credit is Tuesday, November 18, 2025 by 11:59 ET.
For program or meeting questions, contact Meetings@thyroid.org
INSTRUCTIONS FOR CLAIMING CREDIT
Log in to: https://www.prereg.net/2025/ata
Use your ATA account to log in. You may also use your badge number and last name. If you don’t know your badge number you can retrieve it by entering your name, last name, city and zip code (it must match the information on the registration). If you are still having issues retrieving your badge number, please call 678-341-3000.
Once logged in, answer the questions and select the sessions you attended. You will not be able to select more than one session during a block.
The “My Events” tab includes the courses you registered for. “ All Events” includes all the general courses available during the meeting.
MOC Credit
If a course offers MOC credits you must select if you need MOC credit. Once yes is selected, an exam will populate and must get 70 or higher to receive credit. After passing the exam, you must answer survey questions to receive credit.
If you have any issues, email meetings@thyroid.org to get assistance.
Program Objectives
The 2025 Annual Meeting of the American Thyroid Association aims to:
- Provide a professional forum to discuss and apply the most recent knowledge pertaining to basic science and translational research appropriate for basic scientists and clinicians that care for issues related to thyroid.
- Differentiate the changes in guidelines and highlight best practices for adoption into clinical practice.
- Identify new and clinically relevant evidence-based management and treatment(s), using the most up-to-date clinical and scientific information.
Continuing Medical Education Credit Information
Accreditation
The American Thyroid Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA PRA Category 1 Credits™
The American Thyroid Association designates this live activity for a maximum of AMA PRA Category 1 credits: 31.5. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Internal Medicine Board (ABIM) & Amercian Board of Otolaryngology – Head Neck and Surgery (ABOHNS)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program; and Amercian Board of Otolaryngology – Head Neck and Surgery (ABOHNS) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABP MOC credit.
American Board of Surgery Continuous Certification
Successful completion of this CME activity enables the learner to earn credit toward the CME requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.
To submit credit on the learner’s behalf, ATA must have the learner’s date of birth on file.
Commercial Support
The American Thyroid Association acknowledges RGS Healthcare and Esaote for their in-kind support of this educational activity by providing ultrasound machines for the ultrasound workshop(s).
Disclosure Information
In accordance with the ACCME Accreditation Criteria, the American Thyroid Association ensures that anyone in a position to control the content of the educational activity (planners/speakers/authors/discussants/moderators) disclosed all financial relationships with any commercial interest (termed by the ACCME as “ineligible companies”) held in the last 24 months. Please note that first authors were required to collect and submit disclosure information on behalf of all other authors/contributors, if applicable.
The ACCME also requires that ATA manage any reported relevant financial relationships and eliminate the potential for bias during the educational activity. Any relevant financial relationships noted have been mitigated. The disclosure information is intended to identify any commercial relationships and allow learners to form their own judgments. However, if you perceive a bias during the educational activity, please report it on the evaluation.
Faculty Name |
Disclosures |
Sarimar Agosto Salgado | Advisor: Eisai, Exelixis Consultant: Lily Oncology (Ended 12/30/2023) |
Trevor Angell | Research Funding: Immunovant |
Trevor Angell | Research Funding: Immunovant |
Zoltan Antal | Consultant: Bayer |
Guiseppe Barbesino | Consultant: Amgen, Immunovant, Merida Advisor: Argen-X, Crinetics, Viridian |
Antonio Bianco | Consultant: Abbvie; Acella; Aligos; Synthonics; Xeris |
Laura Boucai | Speaker: Vindico Education (Ended 11/17/2023) |
Marcia Brose | Consultant: Bayer, Eisai, Exelixis, Lilly (ended 10/2023) |
Kenneth Burman | Research Funding: TBD |
Naifa Busaidy | Consultant: Exelixis (ended 3/12/25) |
Anne Cappola | Consultant: Cinetics Pharmaceuticals |
Denise Carneiro-Pla | Speaker: Medtronics |
David Cooper | Speaker: MacLeod Pharmaceuticals (ended 2/7/25) |
Carrie Cunningham | Consultant: 3M, Intuitive Robotics |
Terry Davies | Consultant: GLG, Immunovant, Kronus |
Catherine Dinauer | Research Funding: IBSA/Tirosint-SOL |
Chrysoula Dosiou | Consultant: Argenx, Horizon, Immunovant, Septerna, The Column Group (ended 5/17/23); Third Rock Advisor: Sling |
Robert Flavell | Research Funding: Bristol Myers Squibb (ended 12/31/24), Fibrogen Stock Options: Tiller Therapeutics, Topaz Therapeutics |
Kaitlyn Frazier | Research Funding: Allume Biosciences, Baird Medical, OptoSurgical |
Benjamin Gigliotti | Advisor: Eaisi Canada (E: 1/30/25); Amgen (E 6/1/24); Xeris Pharmaceuticals Consultnat: Immunovant (E 12/31/24) |
Whitney Goldner | Research Funding: Siemens (Ended 5/11/24) |
Meredith Hartley | Stock Options: Autobahn Therapeutics |
Meredith Hartley | Stock Options: Autobahn Therapeutics |
Bryan Haugen | Consultant: Sonic Healthcare, Thryv Therapeutics, ThyroSeq Research Funding: Veracyte |
Anthony Hollenberg | Consultant: AstraZeneca; Eli Lilly; NovoNordisk |
Mimi Hu | Research Funding: Eli Lilly |
George Kahaly | Consultant: Immunovant Research Funding: Immunovant; Virdian; Amgen |
Saad Kenderian | Researcher: Kite, Gilead, Juno, BMS, Novartis, Humanigen/Taran, MorphoSys, Tolero, Sunesis, LifEngine, Lentigen Advisor: Kite/Gilead, Calibr, Luminary Therapeutics, Humanigen, Juno/BMS, Capstan Bio, Carisma, and Novartis Royalties: Novartis, Humanigen/Taran , Chymal, MustangBio, Sundero |
Theodore Laetsch | Consultant: Advanced Microbubbles; Bayer; AI |
Sun Lee | Consultant: Alcimed (E 1/10/2025) |
Maya Lodish | Research Funing: Recordati; SA; Eli Lilly &Co Consultant: Neurocrine |
Mark Lupo | Speaker: Eisai; Quidel-Ortho Advisor: Horison-Amgen (ended 12/30/24); Viridian (ended 2/2024) Consultant: Immunovant; Interpace Research Funding: Takeda |
Jennifer Mammen | research funding: Interpace Diagnostics |
Susan Mandel | Consultant: Autobahn |
Elizabeth McAninch | Consultant: Abbvie; Acella |
Ilaria Muller | Consultant: Tourmaline; Argenx Advisor: Amgen (E 9/10/24); Merck (E 9/27/24) Speaker: Alexion Pharma (E12/28/24); |
Yuri Nikiforov | Consultant: Tourmaline; Sonic Healthcare USA |
Julia Noel | Consultant: Medronic; Pulse Biosciences |
Carmelo Nucera | Advisor: AffyImmune Therapeutics |
Theodora Pappa | Consultant: Eisai (Ending 6/30/25) |
Sareh Parangi | Stock Options: Novartis |
Amy Patel Jain | Speaker: Amgen Research Funding: Immuniovant; Viridian |
Zoe Quandt | Consultant: Sanofi |
Gregory Randolph | Research Funding: Eisai; Medtronic Consultant: Getinge; Medtronic |
Jonathon Russell | Consultant: Baxter Scientific |
Steven Sherman | Consultant: Crinetics; Bayer (E 3/19/24); Novartis (E 10/14/24) Research Funding: Eli Lilly |
J. Woody Sistrunk | Consultant: Interspace Diagnostics Research Funding: Ortho Quidel |
John Skaugen | Consultant: Sonic Healthcare |
Julie Ann Sosa | Research Funding: Exelixis and Eli Lilly |
Christine Spitzweg | Advisor: Ipsen, Eisa; Lilly; IBSA; Sanofi; Bayer |
Marius Stan | Consultant: ArgenX; Avilar; Genentech; Immunovant; Lassen; Mingui Pharma; Septerna; Third Rock Ventures; Tourmaline; Tshaka Bio; Viridian |
David Toro-Tobon | Consultant: Immunovant |
Michael Tsang | Ownership Interest: Zegenex |
Ralph Tufano | Consultant: Medtronic; Pulse Biosciences; RGS Healthcare Advisor: RGS Healthcare |
R. Michael Tuttle | Research Funding: Elesta |
Steven Waguespack | Consultant: Bayer |
Lori Wirth | Advisor: Bayer (ended 10/23); Coherus (ended 5/24); Eisai; Eli Lilly (ended 5/24); Ellipses; PDS Biotech; Replimune (ended 12/24) Consultant: EMD Serono (ended 3/24); Illumina (ended 11/23); Nested (ended 10/23); Tubulis (ended 1/25) |
Mingzhao Xing | Baird Medical Inc. |
Mark Zafereo | Research Funding: Eli Lilly; Exelixis; Merck |
Feibi Zheng | Employee: Intuitive Surgical |